Ultima Genomics Unveils ppmSeq Technology for Ultra-Sensitive ctDNA Detection at AACR
Ultima Genomics has announced significant advancements in the detection of minimal residual disease (MRD) using its ppmSeq technology at the American Association for Cancer Research (AACR) meeting. The technology aims to detect small numbers of cancer cells that remain in the body post-treatment, which is crucial for assessing treatment effectiveness and relapse risk. The findings, presented across six abstracts including a plenary session, highlight the performance of ppmSeq in the TRACERx study, a major tumor evolution research project funded by Cancer Research UK. The study involves sequencing genetic data from over 3,200 tumor samples from more than 800 lung cancer patients. Charles Swanton, a professor at The Francis Crick Institute, presented data showing ppmSeq's high analytical sensitivity for ctDNA detection at low parts-per-million levels. Additional data from Labcorp demonstrated the technology's specificity and ability to differentiate between cancerous and non-cancerous samples. 
